Hengrui Pharmaceutical (600276.SH): SHR-4610 injection obtained drug clinical trial approval notice

Zhitongcaijing · 11/07/2025 09:57

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Shanghai Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration (“State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for SHR-4610 injection, which will conduct clinical trials in the near future.

SHR-4610 injection is an innovative anti-tumor drug independently developed by the company. It has shown good anti-tumor activity in pre-clinical animal models and is intended for the treatment of advanced solid tumors. Up to now, SHR-4610 injection-related projects have invested a total of about 7.36 million yuan in R&D.